The arrangement, disclosed in an ethics agreement and court documents, has raised questions about potential conflicts of interest as Kennedy seeks to lead federal agencies that regulate drugmakers.
Also Read: Trump’s Second Term Sparks Market Jitters With Trade, Regulation, Expansion Plans
Kennedy clarified that he is not an attorney in these cases but is entitled to a 10% share of contingency fees.
He has pledged to divest interests in cases involving federal government programs, such as the National Vaccine Injury Compensation Program, but will retain stakes in other lawsuits if cleared by the HHS ethics office.
Kennedy has long criticized government and pharmaceutical industry ties, calling for an end to "regulatory capture." However, his history of vaccine opposition, including calls to revoke COVID-19 vaccine approvals and promotion of lawsuits alleging harm from Gardasil, has amplified scrutiny. Merck maintains that Gardasil is safe, citing extensive scientific evidence supporting its efficacy, according to The New York Times.
Read Next:
Photo: Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
